Patent foramen ovale, subclini- cal cerebrovascular disease, and ischemic stroke in a population-based cohort. J Am Coll Cardiol. 2013;62:35 41. 493. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, Raizner A, Wechsler L; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991 999. 494. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Juni P; PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083 1091. 495. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL: RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092 1100. 496. Acebo E, Val-Bernal JF, Gomez-Roman JJ, Revuelta JM. Clinicopathologic study and DNA analysis of 37 cardiac myxomas: a 28-year experience. Chest. 2003;123:1379 1385. 497. Gowda RM, Khan IA, Nair CK, Mehta NJ, Vasavada BC, Sacchi TJ. Cardiac papillary fibroelastoma: a comprehensive analysis of 725 cases. Am Heart J. 2003;146:404 410. 498. Roberts WC. Primary and secondary neoplasms of the heart. Am J Cardiol. 1997;80:671 682. 499. Reynen K. Cardiac myxomas. N Engl J Med. 1995;333:1610 1617. 500. Howard RA,Aldea GS, Shapira OM, Kasznica JM, Davidoff R. Papillary fibroelastoma: increasing recognition of a surgical disease. Ann Thorac Surg. 1999;68:1881 1885. 501. Sun JP, Asher CR,Yang XS, Cheng GG, Scalia GM, Massed AG, Griffin BP, Ratliff NB, Stewart WJ, Thomas JD. Clinical and echocardiographic Meschia et al Guidelines for the Primary Prevention of Stroke 3821 characteristics of papillary fibroelastomas: a retrospective and prospec- tive study in 162 patients. Circulation. 2001;103:2687 2693. 502. 